01—Abstract
Summary
Summary of the 10-K filed February 15, 2017. Cited figures are marked; the original filing is the authoritative source.
Alnylam Pharmaceuticals, Inc. (ALNY) presented its 2016 10-K, highlighting a significant focus on its RNA interference (RNAi) therapeutic platform.
The company is advancing its "Alnylam 2020" strategy with the goal of becoming a multi-product commercial-stage biopharmaceutical company by the end of 2020, aiming for three marketed products and ten RNAi therapeutic clinical programs. The company's lead candidate, patisiran, for hereditary TTR-mediated amyloidosis (hATTR), is in Phase 3 development with top-line data expected mid-2017, and potential regulatory submissions planned for late 2017. Significant R&D investments continued in 2016, reflecting the advancement of a broad pipeline across three strategic therapeutic areas: Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases.
The company also detailed progress in its manufacturing capabilities and global expansion, including its operational manufacturing facility for patisiran and construction of a new drug substance facility. Despite a substantial net loss of $410.1 milliona for 2016, driven by significant R&D expenses, Alnylam maintained a strong cash position of $942.6 million in cash, cash equivalents, and marketable securities at year-end, supported by strategic collaborations with companies like Sanofi Genzyme and The Medicines Company.
02—Key points
Key Highlights
- Alnylam is strategically positioned to become a multi-product commercial-stage biopharmaceutical company by 2020, with its "Alnylam 2020" strategy.
- Patisiran, the lead product candidate for hATTR amyloidosis, is in Phase 3 (APOLLO study) with top-line data anticipated mid-2017 and regulatory submissions planned for late 2017.
- Significant investment in Research and Development ($382.4 million in 2016) continues to drive pipeline advancement across Genetic Medicines, Cardio-Metabolic Diseases, and Hepatic Infectious Diseases.
- The company is expanding its manufacturing infrastructure, including a new drug substance manufacturing facility, to support future commercialization.
- Alnylam ended 2016 with a strong liquidity position, holding $942.6 million in cash, cash equivalents, and marketable securities.
- Key strategic alliances with Sanofi Genzyme and The Medicines Company provide crucial support for development and commercialization efforts.
- The company experienced a net loss of $410.1 million for 2016, primarily due to substantial R&D expenditures necessary for pipeline development.
03—One dollar
04—Financials
Financial Highlights
Figures from 10-KFY2016filed February 15, 2017Financial Statements
FY2016 against FY2015
| Line item | FY2016FY2015 | Change |
|---|---|---|
| Revenue | $47.16M— | — |
| R&D Expenses | $382.39M$276.50M | +38.3% |
| SG&A Expenses | $89.35M— | — |
| Operating Expenses | $471.75M$337.11M | +39.9% |
| Operating Income | -$424.59M-$296.01M | −43.4% |
| Net Income | -$410.11M-$290.07M | −41.4% |
| EPS (Basic) | $-4.79$-3.45 | −38.8% |
| Shares Outstanding (Basic) | 85.60M83.99M | +1.9% |
05—Questions
Frequently Asked Questions
What is Alnylam's primary focus and future strategy?
Alnylam's primary focus is on developing novel therapeutics based on RNA interference (RNAi) technology. Its "Alnylam 2020" strategy aims to become a multi-product commercial-stage biopharmaceutical company by the end of 2020, with a pipeline of ten clinical programs, including at least four in late-stage development, and three marketed products.
What is the status of Alnylam's lead product candidate, patisiran?
Patisiran, targeted for hereditary TTR-mediated amyloidosis (hATTR), is in a Phase 3 clinical trial called APOLLO. Alnylam expected to report top-line data in mid-2017 and planned to submit its first New Drug Application (NDA) and Marketing Authorization Application (MAA) by the end of 2017.
How is Alnylam funding its extensive research and development efforts?
Alnylam funds its operations through a combination of equity financings and strategic alliances. Significant collaborations with partners like Sanofi Genzyme and The Medicines Company provide upfront payments, research funding, and potential milestone payments, which are critical for advancing its pipeline.
What are the key financial highlights from the 2016 10-K filing?
For the year ended December 31, 2016, Alnylam reported a net loss of $410.1 million, driven by R&D expenses of $382.4 million. The company maintained a strong cash position, ending the year with $942.6 million in cash, cash equivalents, and marketable securities. Net revenues from collaborators were $47.2 million, primarily from its strategic alliances.
06—Continue